Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

@article{Wilkie2012DualTO,
  title={Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling},
  author={S. Wilkie and May C. I. van Schalkwyk and S. Hobbs and D. Davies and S. Stegen and A. Pereira and Sophie E Burbridge and C. Box and S. Eccles and J. Maher},
  journal={Journal of Clinical Immunology},
  year={2012},
  volume={32},
  pages={1059-1070}
}
  • S. Wilkie, May C. I. van Schalkwyk, +7 authors J. Maher
  • Published 2012
  • Biology, Medicine
  • Journal of Clinical Immunology
  • PurposeChimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in cancer immunotherapy. In this context, CAR-mediated CD3ζ signaling is sufficient to elicit cytotoxicity and interferon-γ production while the additional provision of CD28-mediated signal 2 promotes T-cell proliferation and interleukin (IL)-2 production. This compartmentalisation of signaling opens the possibility that complementary CARs could be used to focus T-cell activation within the tumor… CONTINUE READING
    Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
    • 368
    • Highly Influenced
    • PDF
    Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
    • 204
    • Highly Influenced
    • PDF
    The Principles of Engineering Immune Cells to Treat Cancer
    • 396
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 52 REFERENCES
    A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
    • 855
    • PDF
    Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector
    • 1,026
    • PDF
    Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    • 453